An Automated Drug Concentration Screening and Quality Assurance Program for Clinical Trials

Therapeutic Innovation & Regulatory Science

Volumn 33, Issue 1, 1999, Pages 273-279

  Grasela, Thaddeus H ^a   Antal, Edward J ^b   Fiedler Kelly, Jill ^a   Foit, Darcy J ^a   Barth, Brenda ^a   Knuth, Dean W ^b   Carel, Barbara J ^b   Cox, Steven R ^b  

^a Pharmaceutical Outcomes Res Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

AIDS; Clinical trials; Pharmacokinetics; Quality assurance

Indexed keywords

EID: 84993734773     PISSN: 21684790     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300131     Document Type: Article

References (17)

1. Hashimoto Y Sheiner LB Designs for population pharmacodynamics: value of pharmacokinetic data and population analyses. J. Pharmacokinet Biopharm. 1991; 19(3):333–353.
2. Peck C Barr WH Benet LZ Collins J Desjardins RE Furst DE, et al Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. J Pharm Sci. 1992; 81(6):605–610.
3. Ette EI Sun H Ludden TM Design of population pharmacokinetic studies. Proc Am Stat Assoc (Biopharmaceutics Section). 1994; 487–492.
4. Aarons L. Population pharmacokinetics: theory and practice. Br J Clin Pharmacol. 1991; 32: 669–670.
5. Steimer JL Vozeh S Racine-Poon A, et al The population approach: rationale, methods, and applications in clinical pharmacology and drug development (Chapter 15). In: Welling PG, Balant LP, ed. Pharmacokinetics of Drugs. (Handbook of Experimental Pharmacology). Berlin Heidelberg: Springer-Verlag; 1991;(110):404–451.
6. Sheiner LB Rosenberg B Marathe VV Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977; 5(5):445–475.
7. Mandema JW Verotta D Sheiner LB Building population pharmacokinetic pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20(5):511–528.
8. Grasela TH Antal EJ Ereshefsky L Wells BG Evans RL Smith RB An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol & Ther. 1987; 42(4):433–441.
9. Schmith VD Fiedler-Kelly J Phillips L Grasela TH Prospective use of population pharmacokinetics/pharmacodynamics in the development cisatracurium. Pharm Res. 1997; 14(1):91–97.
10. Antal EJ Grasela TH Smith RB An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly. Clin Pharmacol & Ther. 1989; 46(5):552–559.
11. Aarons L Balant LP Mentré F Morselli PL Rowland M Steimer JL, et al Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol. 1996; 49: 251–254.
12. Rombout F. Good pharmacokinetic practice (GPP) and logistics: a continuing challenge. In: Balant LP, Aarons L, eds. The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose. Brussels: Commission of the European Communities, European Cooperation in the Field of Scientific and Technical Research; 1997.
13. Cheng CL Smith DE Carver PL Cox SR Watkins PB Blake DS, et al Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin Pharmacol Ther. 1997; 61(5):531–543.
14. Staton BA Friis JM Carel BJ Rettig J Hanson G Adams WJ Determination of delavirdine and metabolite in human plasma by HPLC fluorescence detection. Pharm Res. 1994; 11(10) (suppl: S19).
15. Staton BA Johnson MG Friis JM Adams WJ Simple rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatography B: Biomed Applica. 1995; 99–106.
16. Laplanche R Fertil B Nüesch E Jais JP Niederberger W Steimer JL Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther. 1991; 50(1):39–54.
17. Ette EI Ludden TM Population pharmacokinetic modeling: the importance of informative graphics. Pharmaceut Res. 1995; 12(12):1845–1855.